SALIM VIRANI to Drug Costs
This is a "connection" page, showing publications SALIM VIRANI has written about Drug Costs.
Connection Strength
2.584
-
Implications of cost-effectiveness analyses of lipid-lowering therapies: From the policy-maker's desk to the patient's bedside. Prog Cardiovasc Dis. 2019 Sep - Oct; 62(5):406-413.
Score: 0.651
-
Eligibility and Cost for Icosapent Ethyl Based on the REDUCE-IT Trial. Circulation. 2019 03 05; 139(10):1341-1343.
Score: 0.622
-
Applicability and Cost Implications for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Based on the ODYSSEY Outcomes Trial. Circulation. 2019 01 15; 139(3):410-412.
Score: 0.616
-
Association Between Modifiable Risk Factors and Pharmaceutical Expenditures Among Adults With Atherosclerotic Cardiovascular Disease in the United States: 2012-2013 Medical Expenditures Panel?Survey. J Am Heart Assoc. 2017 Jun 09; 6(6).
Score: 0.551
-
National Trends in Nonstatin Use and Expenditures Among the US Adult Population From 2002 to 2013: Insights From Medical Expenditure Panel?Survey. J Am Heart Assoc. 2018 01 22; 7(2).
Score: 0.144